Image

Characterization of Different Phenotypes of Microvascular Dysfunction and Their Impact on Angina Severity in Patients With Chronic Angina in the Absence of Obstructive Coronary Artery Disease.

Characterization of Different Phenotypes of Microvascular Dysfunction and Their Impact on Angina Severity in Patients With Chronic Angina in the Absence of Obstructive Coronary Artery Disease.

Recruiting
18-85 years
All
Phase N/A

Powered by AI

Overview

The aim of the present study will be to identify different phenotypes of microvascular dysfunction and their associations with the severity of anginal symptoms assessed through the Seattle Angina Questionnaire(SAQ-7).

Description

After administration of unfractionated heparin (100UI/Kg), a special pressure guide (Pressure Wire X, Abbott), equipped with a distal sensor capable of measuring pressure and temperature, will be introduced inside the anterior descending branch (IVA) of the left coronary artery and hyperemia will be induced by intravenous infusion of adenosine. The IMR will be calculated using the thermodilution technique, and is given by the product between the mean distal pressure, in the left anterior descending coronary artery, and the mean transit time (Tmn) during maximal hyperemia.

During the procedure, additional coronary physiological indices will be calculated such as:

  • Quiescent full cycle flow ratio (RFR), - Fractional flow reserve (FFR),
  • Coronary flow reserve (CFR)

In order to identify different phenotypes of microvascular dysfunction, as follows:

  • Phenotype A: Patients with IMR>25, CFR <2 and FFR>0.80 (concordant pure-microvascular pathological results)
  • Phenotype B: patients with IMR>25, CFR>2 and FFR>0.80 (increased microvascular hyperemic resistance, maintenance of microvascular reactivity)
  • Phenotype C: Patients with IMR 25, CFR 2 and FFR>0.80 (normal hyperemic resistance and reduced reactivity) All these phenotypes can also be combined with pathological FFR measures (<0.80) (phenotypes A1, B1, C1).

Eligibility

Inclusion Criteria:

Patients who meet all of the following criteria will be considered for study participation:

        Age ≥18 and <85 years. Chronic coronary syndrome (including patients with anginal
        equivalents) Angina CCS class II-IV Evidence of inducible reversible ischemia in
        noninvasive trials
        Availability of the following measurements:
          -  Microvascular resistance index (IMR)
          -  Quiescent full cycle flow ratio (RFR),
          -  fractional flow reserve (FFR),
          -  Coronary flow reserve (CFR) Willingness to participate and sign the informed consent
             document prior to the procedure.
        Exclusion Criteria:
        At least one of the following:
        Pregnancy or breastfeeding. Medical or psychological conditions that would compromise
        proper and orderly participation.
        Left ejection fraction less than 30% Prior coronary artery bypass surgery (CABG)
        Decompensated congestive heart failure (CHF) Chronic or acute renal failure with creatinine
        >2mg/dl Severe valve disease Patients with comorbidities limiting life expectancy to less
        than one year.

Study details
    Angina CCS Classe II-IV - IMR
    RFR
    FFR
    CFR

NCT05686707

Federico II University

7 March 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.